Syncona (via Bidco) Agrees to Acquire Freeline Therapeutics
February 12, 2024
Syncona, through a wholly owned Bidco subsidiary, will acquire all remaining shares of Freeline Therapeutics for $6.50 per ADS in a take-private transaction. Freeline shareholders overwhelmingly approved the scheme; the deal is expected to become effective after UK court sanctioning and will result in Freeline delisting from Nasdaq to allow private development of its gene-therapy programs.
- Buyers
- Syncona Ltd, Bidco 1354 Limited (wholly owned subsidiary of Syncona Portfolio Limited)
- Targets
- Freeline Therapeutics Holdings plc
- Sellers
- Freeline shareholders (public shareholders not already owned by Syncona Portfolio)
- Industry
- Biotechnology
- Location
- Hertfordshire, United Kingdom
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Neurocrine Biosciences to Acquire Celeno Therapeutics
April 7, 2026
Healthcare Services
Neurocrine Biosciences entered into a definitive all-cash agreement to acquire Celeno Therapeutics for approximately $2.9 billion. The deal is structured as a tender offer and is expected to close within ~90 days, subject to Hart-Scott-Rodino antitrust clearance and a majority of Celeno shares being tendered.
-
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion
April 6, 2026
Healthcare Services
Neurocrine Biosciences entered into a definitive agreement to acquire Soleno Therapeutics in an all-cash transaction valued at approximately $2.9 billion. The deal adds Soleno’s first-in-class therapy VYKAT XR (diazoxide choline) for hyperphagia in Prader-Willi syndrome to Neurocrine’s commercial portfolio, and is expected to close within 90 days subject to customary conditions and regulatory approvals.
-
Biogen Acquires Alcyone Therapeutics
September 19, 2025
Medical Devices
Biogen has acquired Alcyone Therapeutics to obtain the ThecaFlex DRx intrathecal drug‑delivery system, integrating Alcyone employees into Biogen’s product delivery solutions team. Alcyone will receive $85 million upfront plus contingent milestone payments; Biogen will handle development, commercialization and manufacturing of ThecaFlex DRx while Alcyone’s remaining therapeutic assets are being divested into Neela Therapeutics.
-
Lonza Group AG Acquires Synaffix B.V.
June 1, 2023
Biotechnology
Lonza Group AG has acquired Synaffix B.V., a Netherlands-based biotech company that commercialises a clinical-stage antibody-drug conjugate (ADC) technology platform. The deal brings Synaffix's ADC bioconjugation technology into Lonza's integrated ADC development and manufacturing offering to accelerate discovery, development, scale-up and commercialization of ADCs.
-
Syncona to Acquire Applied Genetic Technologies Corporation
October 23, 2022
Biotechnology
Syncona Limited will acquire Applied Genetic Technologies Corporation (AGTC) via a tender offer, paying $0.34 per share in cash upfront (approximately $23.5 million) with contingent value rights (CVRs) that could provide up to an additional $0.73 per share (up to $50.0 million) for total potential consideration of up to $1.07 per share. The transaction, unanimously approved by AGTC’s board, will take AGTC private and is intended to advance AGTC's retinal gene therapy programs amid funding challenges for the public company.
-
AbbVie Acquires Syndesi Therapeutics
March 1, 2022
Biotechnology
AbbVie has acquired Syndesi Therapeutics for up to US$1.0 billion, including US$130 million upfront, to strengthen its neuroscience portfolio and accelerate Syndesi's lead SV2A program SDI-118 into later-stage development. Syndesi was a Novo Seeds / UCB spin-out backed by Novo Holdings and a syndicate of Belgian and international investors.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.